Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03105479
Other study ID # AC-061A303
Secondary ID 2015-004805-17
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date April 14, 2017
Est. completion date April 17, 2018

Study information

Verified date March 2019
Source Actelion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cadazolid has demonstrated activity against a bacteria named Clostridium difficile in animal studies. The results of a first study conducted in adult patients have suggested efficacy of the new antibiotic, cadazolid, in the treatment of diarrhea caused by this bacteria. This is the first study of cadazolid in children. The overall purpose of this study is to provide reassurance on the safety and efficacy of cadazolid in children suffering from infection due to Clostridium difficile.


Description:

This multicenter, study will be run into two parts. Both parts will be run in consecutive age cohorts, starting from the oldest age categories(12 to < 18 years old) to the youngest (birth to < 3 months).

- Part A is an open-label, dose finding part to be conducted in at least 24 subjects.

- Part B follows a randomized, assessor-blinded, parallel-group design with vancomycin used as an active comparator. Part B will be conducted in about 176 children.

In both parts, the treatment period will be 10 days and will be followed by a Follow-up period of 28-32 days.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date April 17, 2018
Est. primary completion date April 17, 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Key Inclusion Criteria:

- Signed informed consent by parents or legally authorized representatives (LAR) and assent by the child according to local requirements prior to initiation of any study-mandated procedure.

- Male or female from birth to < 18 years of age, diagnosed with Clostridium Difficile-associated diarrhea (CDAD).

- Females of childbearing potential must have a negative pregnancy test at screening and must agree to use an adequate and reliable method of contraception.

Key Exclusion Criteria:

- Positive Rotavirus test for subjects < 5 years.

- Fulminant or life-threatening CDAD.

- More than one previous episode of CDAD in the 3 month period prior to enrollment / randomization.

- Antimicrobial treatment active against CDAD administered within 24 h prior to screening except for metronidazole treatment failures (MTF).

- Subjects with body weight < 3 kg.

- Inflammatory bowel disease, chronic abdominal pain, or chronic diarrhea of any etiology.

- Fecal microbiota transplant (FMT), immunoglobulin therapy, or any investigational drug to prevent or treat CDAD within 1 month period (or 5 half-lives in case of investigational drug, whichever is longer) prior to enrollment / randomization.

- Monoclonal antibodies against C. difficile within 6 months prior to enrollment / randomization.

- Previous vaccination against C. difficile.

- Known mental disorders.

- Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study, or compliance with the protocol.

Study Design


Intervention

Drug:
Cadazolid
Granules for oral suspension to be administered twice daily
Vancomycin capsule
Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
Vancomycin solution
Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day

Locations

Country Name City State
Belgium Universitair Ziekenhuis Brussel - Kinderziekenhuis Jette
Canada Infection Prevention & Control, AGW5 Foothills Medical Center 1403 29th Street N.W. Calgary
Czechia FN Brno Brno
Hungary Egyesített Szent István és Szent László Kórház - Rendelointézet / Gyermekinfektológiai Osztály Budapest
Hungary Pándy Kálmán Megyei Kórház Gyula
Italy Ospedale Buzzi Milano
Italy Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu Roma
Poland Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza Bydgoszcz
Poland Specjalistyczny Zespól Opieki Zdrowotnej nad Matka i Dzieckiem Poznan
Poland Gabinet Lekarski Bartosz Korczowski Rzeszow
Poland Klinika Gastroenterologii, Hepatologii, Zaburzen Odzywiania i Pediatrii, Instytut "Pomnik - Centrum Zdrowia Dziecka" Warsaw
Romania Institutul National De Boli Infectioase "Prof. Dr. Matei Bals", sectia IX pediatrie Bucharest
Romania Spitalul Clinic de Boli Infectioase "Sfanta Parascheva" Iasi, Clinica de Boli Infectioase I, Iasi
Spain Hospital Sant Joan de Déu, Esplugues Barcelona
Spain Hospital Universitario Infantil LA PAZ Madrid
United States University of Chicago, Dept. Of Medicine Chicago Illinois
United States Texas Children's Hospital Feigin Cente Houston Texas
United States Snake River Research, PLLC Idaho Falls Idaho
United States Louisiana State University Health Sciences Center - Shreveport Shreveport Louisiana
United States SUNY Upstate Medical University - Upstate Golisano Children's Hospital (GCH) - Pediatric Designated AIDS Center Syracuse Ohio

Sponsors (1)

Lead Sponsor Collaborator
Actelion

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Czechia,  Hungary,  Italy,  Poland,  Romania,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Cure Rate During Part B This is the percentage of participants in part B reported as with a clinical cure. Clinical Cure is defined as: • <3 unformed bowel movement (UBM) per day (or no water diarrhea if subjects < 2 years of age), for at least 2 consecutive days between first dose of study treatment up to end of treatment (EOT) (inclusive) AND • Subject remains well up to EOT + 2 days (inclusive) based on investigator judgment AND • No need for additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) between first dose of study treatment up to EOT + 2 days (inclusive). percentage of subjects with a clinical cure Day 10 (End of Treatment) + 2 days
Primary Maximal Plasma Concentration (Cmax) of Cadazolid During Part A Blood samples are collected at different timepoints on Day 10 for the determination of cadazolid Cmax after 10 days of treatment. Day 10 (End of Treatment)
Primary Time to Reach Cmax (Tmax) of Cadazolid During Part A Blood samples are collected at different timepoints to determine the time when the maximal plasma concentration of cadazolid is reached. Day 10 (End of Treatment)
Primary Area Under the Plasma Concentration Time Curve (AUC) of Cadazolid During Part A Blood samples are collected at different timepoints for the determination of the cadazolid AUC over one dosing interval (0-12h) on Day 10. Day 10 (End of Treatment)
Primary Fecal Concentrations of Cadazolid During Part A A fecal sample is collected as the end-of-treatment visit in all participants in Part A. Day 10 (End of Treatment)
Secondary Clinical Cure Rate During Part A This is the percentage of participants in Part A reported as with a clinical cure. Clinical Cure is defined as: • <3 unformed bowel movement (UBM) per day (or no water diarrhea if subjects < 2 years of age), for at least 2 consecutive days between first dose of study treatment up to end of treatment (EOT) (inclusive) AND • Subject remains well up to EOT + 2 days (inclusive) based on investigator judgment AND • No need for additional antimicrobial treatment active against Clostridium difficile-associated diarrhea (CDAD) between first dose of study treatment up to EOT + 2 days (inclusive). Day 10 (End of Treatment) + 2 days
Secondary Sustained Clinical Cure Rate During Part A and Part B This is the percentage of participants in Parts A and B reported as with sustained clinical cure. Sustained clinical cure is defined as • Clinical Cure and no Recurrence until 30 days after the last study drug intake (end of study). Day 40 (on average)
Secondary Recurrence Rate During Part A and Part B This is the percentage of participants in Parts A and B assessed as having a recurrence out of subjects meeting the criteria for Clinical Cure. Recurrence is defined as: • Clinical Cure AND New episode of diarrhea with = 3 UBMs (or watery diarrhea if subject < 2 years) on any day between EOT + 3 days and end of study AND • Stool test showing positive C. difficile (as defined in Inclusion Criterion 4), AND •Antimicrobial treatment active against CDAD started between EOT + 3 days and end of study. Day 40 (on average)
Secondary Time to Recurrence in Part B This it the time (in days) elapsed between the last dose of study drug and the onset day of new episode of diarrhea reported as Kaplan-Meier estimates (KM estimates) Day 40 (on average)
Secondary Time to Resolution of Diarrhea in Part B This is the time (in days) elapsed between the first dose of study treatment and the resolution of diarrhea and reported as Kaplan-Meier estimates (KM estimates). The date of resolution of Diarrhea (ROD) is defined as the date of the first day of the 2 consecutive days on treatment with < 3 UBM (or no watery diarrhea for subjects < 2 years of age). Time to ROD is the time (in days) elapsed between the first dose of study treatment and the ROD Day 10
Secondary Adverse Events Leading to Premature Discontinuation of Study Treatment Number of participants who prematurely discontinued the study treatment due to an adverse event Up to Day 10
Secondary Marked Abnormalities in Clinical Laboratory Parameters Number of participants with any marked abnormalities in laboratory parameters up to 7 days after end of treatment Day 17 (on average)
Secondary Marked Abnormalities in Vital Signs Number of subjects with any treatment-emergent abnormalities in vital signs (up to 7 days after end of treatment) Day 17 (on average)
Secondary Treatment-emergent Adverse Events (TEAES) Number of subjects with any TEAEs. A TEAE is any adverse event temporally associated with the use of study treatment (from study treatment initiation until 7 days after study treatment discontinuation) whether or not considered by the investigator as related to study treatment. Day 17 (on average)
See also
  Status Clinical Trial Phase
Completed NCT02214771 - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients N/A
Withdrawn NCT01552668 - Fidaxomicin to Prevent Clostridium Difficile Colonization Phase 4
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Not yet recruiting NCT03586206 - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended NCT03350711 - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn NCT03643887 - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients Phase 2
Terminated NCT04000555 - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Phase 4
Terminated NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 Phase 1/Phase 2
Completed NCT03710694 - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) N/A
Completed NCT02865616 - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) Phase 1
Recruiting NCT04940468 - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology N/A
Completed NCT02589847 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection Phase 2
Not yet recruiting NCT01942447 - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis N/A
Active, not recruiting NCT02086916 - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection N/A
Completed NCT01230957 - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults Phase 2
Completed NCT01241552 - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) Phase 3
Not yet recruiting NCT04567134 - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed NCT04075422 - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting NCT03712722 - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting NCT05192148 - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile N/A